Mini Review ARTICLE

Front. Oncol., 11 August 2014 |

Biomarkers that currently affect clinical practice in lung cancer: EGFR, ALK, MET, ROS-1, and KRAS

  • 1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
  • 2London Regional Cancer Program, Department of Medical Oncology, London Health Sciences Centre, London, ON, Canada

Lung cancer remains the most lethal malignancy in the world. Despite improvements in surgical treatment, systemic therapy, and radiotherapy, the 5-year survival rate for all patients diagnosed with lung cancer remains between 15 and 20%. Newer therapeutic strategies rely on specific molecular alterations, or biomarkers, that provide opportunities for a personalized approach to specific patient populations. Classification of lung cancer is becoming increasingly focused on these biomarkers, which renders the term “non-small cell lung” cancer less clinically useful. Non-small cell lung cancer is now recognized as a complex malignancy and its molecular and genomic diversity allows for patient-centered treatment options. Here, we review advances in targeted treatment of lung adenocarcinoma with respect to five clinically relevant biomarkers – EGFR, ALK, MET, ROS-1, and KRAS.

Keywords: EGFR, ALK, Met, ROS-1, KRAS, lung adenocarcinoma, biomarkers

Citation: Korpanty GJ, Graham DM, Vincent MD and Leighl NB (2014) Biomarkers that currently affect clinical practice in lung cancer: EGFR, ALK, MET, ROS-1, and KRAS. Front. Oncol. 4:204. doi: 10.3389/fonc.2014.00204

Received: 26 May 2014; Accepted: 16 July 2014;
Published online: 11 August 2014.

Edited by:

Barbara Melosky, British Columbia Cancer Agency, Canada

Reviewed by:

Sacha I. Rothschild, University Hospital Basel, Switzerland
Ricardo Martinez, Eli Lilly, USA

Copyright: © 2014 Korpanty, Graham, Vincent and Leighl. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Natasha B. Leighl, Division of Medical Oncology, Princess Margaret Cancer Centre, 5-105 610 University Avenue, Toronto, ON M5G 2M9, Canada e-mail: